Cagrilintide (5 mg Vial)

Cagrilintide Information Chart

Cagrilintide is administered at 600 mcg–4.5 mg weekly by subcutaneous Research in educational protocols, starting low and titrating upward. A 5 mg vial reconstituted with bacteriostatic water yields about 1.67 mg/mL. This information is for research and educational use only.

Cagrilintide is a long‑acting acylated analogue of the pancreatic hormone amylin, designed for once‑weekly subcutaneous administration. It activates central amylin receptors to promote satiety, slow gastric emptying, and reduce food intake. In phase 2 and phase 3 trials, cagrilintide produced Information‑dependent weight loss with a predominantly gastrointestinal side‑effect profile.

Educational guide for reconstitution and weekly Information

Standard / Gradual Approach (3 mL = ~1.67 mg/mL)

Route: Subcutaneous Research. Frequency: Once weekly on a consistent day.

Phase	Daily Blend (mg)	Units	Volume (mL)
Weeks 1–2	0.6 mg	36 units	0.36 mL
Weeks 3–4	1.2 mg	72 units	0.72 mL
Weeks 5–6	2.4 mg	144 units	1.44 mL
Weeks 7–16 (Maintenance)	4.5 mg	270 units	2.70 mL

Note: Information above 1.0 mL (100 units) require a 3 mL syringe with an appropriate subcutaneous needle (e.g., 25–27G, ½–⅝ inch) rather than a standard U‑100 insulin syringe. For lower starting Information (≤72 units), a U‑100 insulin syringe provides excellent accuracy.

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming or vigorous agitation.
3. Gently swirl or roll until fully dissolved (do not shake).
4. Label with date and concentration; refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
5. Use within 30 days of reconstitution; discard if cloudy or particulate matter appears.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Plan based on an 8–16 week weekly protocol with gradual titration.

Weeks 1–4 (Information≤72 units): U-100 insulin syringes work well
Weeks 5+ (Information >100 units): 3 mL syringes with 25–27G subcutaneous needles
Per week: 1 syringe
8 weeks: 8 syringes
12 weeks: 12 syringes
16 weeks: 16 syringes

Concise summary of the once‑weekly regimen.

Goal: Support satiety, reduce food intake, and promote weight management over time.
Schedule: Weekly subcutaneous Research for 12–16 weeks (or longer as appropriate).
Information Range: 0.6–4.5 mg weekly with gradual titration every 2 weeks.
Reconstitution: 3.0 mL per 5 mg vial (~1.67 mg/mL) for practical volume measurements.
Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw cycles.

Suggested weekly titration approach based on clinical trial designs.

Start: 0.6 mg weekly for the first 2 weeks to assess tolerability.
Escalate: Double the Information every 2 weeks (0.6 → 1.2 → 2.4 → 4.5 mg) as tolerated.
Target: 4.5 mg weekly by Weeks 7–8; maintain at this Information.
Frequency: Once per week (subcutaneous) on the same day each week.
Timing: Any consistent time; rotate Research sites.

Proper storage preserves peptide integrity and potency.

Practical considerations for consistency and tolerability.

Use new sterile syringes for each Research; dispose in a sharps container.
Rotate Research sites (abdomen, thighs, upper arms) weekly to reduce local irritation.
Gradual Information escalation minimizes gastrointestinal side effects such as nausea.
Document weekly Information, Researchsite, and any adverse effects to maintain consistency.
For maintenance Information requiring >1.0 mL, ensure you have appropriately sized syringes (3 mL).

Cagrilintide is an acylated, long‑acting analogue of amylin—a hormone co‑secreted with insulin from pancreatic beta cells. Native amylin promotes satiation, slows gastric emptying, and inhibits postprandial glucagon secretion. By acting on central amylin receptors (particularly in the area postrema and hindbrain), cagrilintide reduces appetite and energy intake. Lipid modifications extend its half‑life to approximately 160–195 hours, enabling once‑weekly Information.

Observations from phase 2 and phase 3 clinical trials.

Weight reduction: In the phase 2 trial, cagrilintide 4.5 mg weekly produced approximately 10.8% body weight loss over 26 weeks versus 3.0% with placebo.
Combination therapy: When combined with semaglutide 2.4 mg (CagriSema), phase 3 REDEFINE trials showed approximately 20% weight loss at 68 weeks, exceeding results with either agent alone.
Information-dependent efficacy: Higher Information (2.4–4.5 mg) demonstrate greater weight loss than lower Information (0.3–1.2 mg).
Side effects: Primarily gastrointestinal—nausea, vomiting, diarrhea, and constipation—which are generally mild-to-moderate and transient. Gradual titration helps minimize these effects.
Research-site reactions: Occasional mild redness or irritation at subcutaneous Research sites.0

Complementary strategies for optimal outcomes.

Pair with a balanced, protein‑forward diet tailored to individual energy needs.
Combine resistance training and aerobic activity to support metabolic health and preserve lean mass.
Prioritize adequate sleep (7–9 hours) and stress management for adherence and recovery.
Monitor hydration and electrolytes, especially if experiencing gastrointestinal side effects.

General subcutaneous guidance from clinical best‑practice resources

Clean the vial stopper and skin with alcohol; allow to air dry completely.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
Do not aspirate for subcutaneous Research; inject slowly and steadily.
Hold for 5–10 seconds before withdrawing the needle to ensure complete delivery.
Rotate sites systematically (abdomen, thighs, upper arms) each week to avoid lipohypertrophy.

We recommend Vitality Labs Peptides for high-purity 5-Amino-1MQ (50 mg).

Why Vitality Labs Peptides?

This content is for educational purposes only and is not medical advice.

The Lancet (2021)

— Once‑weekly cagrilintide for weight management: phase 2 Information‑finding trial (Lau et al.)

Int J Mol Sci (2024)

— Amylin, another important neuroendocrine hormone for treatment of diabesity

PMC (2022)

— Mediators of amylin action in metabolic control

The Lancet (2021)

— Cagrilintide phase 2 trial: 10.8% weight loss at 4.5 mg Information over 26 weeks

N Engl J Med (2025)

— REDEFINE 1: Coadministered cagrilintide and semaglutide in adults with overweight or obesity

PMC (2022The Lancet (2021)

— Cagrilintide + semaglutide phase 1b trial: safety, tolerability, pharmacokinetics (Enebo et al.)

J Med Chem (2021)

— Development of cagrilintide: a long‑acting amylin analogue

Brain Res Rev (2005)

— Pancreatic amylin as a centrally acting satiating hormone

PMC (2006)

— Pancreatic signals controlling food intake: insulin, glucagon, and amylin

PMC (2016)

— Amylin‑mediated control of glycemia, energy balance, and cognition

PMC (2024)

— Clinical pharmacokinetics of semaglutide: systematic review (includes cagrilintide PK data)

NCBI Bookshelf

— REDEFINE 2: Cagrilintide–semaglutide in adults with overweight/obesity and type 2 diabetes

CDC

— Vaccine administration: subcutaneous Research technique and site guidance

CDC (PDF)

— You Call the Shots: subcutaneous Research diagram and best practices

PMC (2019)

— Subcutaneous drug delivery: pharmacologic considerations and techniques

American College of Cardiology (2025)

— REDEFINE 1 and REDEFINE 2 journal scan summary

The Lancet (2023)

— Efficacy and safety of CagriSema in type 2 diabetes: phase 2 trial (Frias et al.)

PMC (2024)

— Efficacy and safety of cagrilintide and CagriSema: systematic review and meta‑analysis

Vitality Lab Peptides

— Cagrilintide (5 mg) Research (quality and batch documentation)
View Source